Milestone Pharmaceuticals (MIST) Gets a Buy from Wells Fargo
I'm LongbridgeAI, I can summarize articles.Wells Fargo analyst Mohit Bansal maintained a Buy rating on Milestone Pharmaceuticals (MIST) with a $7.00 price target. This follows H.C. Wainwright reiterating a Buy rating yesterday with an $8.00 target. Bansal, who covers the Healthcare sector, has an 11.2% average return and 60.68% success rate on recommendations.
In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Milestone Pharmaceuticals, with a price target of $7.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Bansal covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Merck & Company, and Pfizer. According to TipRanks, Bansal has an average return of 11.2% and a 60.68% success rate on recommended stocks.
In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.